340/V601 - MASONRY STABILISING SOLUTION

Hazard statements (CLP)

H226, H304, H336

Code

Statements

H226

Flammable liquid and vapour

SECTION 2: Hazards identification

Adverse physicochemical, human health and environmental effects

No additional information available

2.2 Label elements

Labelling

Hazard pictograms

GHS02 GHS07 GHS08

Signal word

Danger

Contains

Hydrocarbons, C9-C11, n-alkanes, isoalkanes, cyclics, <2% aromatics

Hazard statements

H226 - Flammable liquid and vapour. H304 - May be fatal if swallowed and enters airways. H336 - May cause drowsiness or dizziness.

Precautionary statements

P101 - If medical advice is needed, have product container or label at hand. P102 - Keep out of reach of children. P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. P233 - Keep container tightly closed. P261 - Avoid breathing dust/fume/gas/mist/vapours/spray. P271 - Use only outdoors or in a well-ventilated area. P280 - Wear protective gloves/protective clothing/eye protection/face protection. P303+P361+P353 - IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water/shower. P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P501 - Dispose of contents/container to hazardous or special waste collection point, in accordance with local, regional, national and/or international regulation.

Supplemental label elements

EUH066 - Repeated exposure may cause skin dryness or cracking.

Other hazards

This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %